Oncologic therapy related adverse events - Revision history

SeanDenny: /* Gemtuzumab ozogamicin (Mylotarg) */

2020-12-15T00:21:56Z

Gemtuzumab ozogamicin (Mylotarg)

← Older revision		Revision as of 00:21, 15 December 2020
Line 202:		Line 202:
	*Adverse Events:		*Adverse Events:
	**[[Thrombocytopenia]]		**[[Thrombocytopenia]]
	**[[~~Transaminitis~~]]		**Abnormal [[LFTs]]
	**Veno-oclusions		**Veno-oclusions


	===Brentuximab vedotin (Adcetris)===		===Brentuximab vedotin (Adcetris)===

2020-03-06T18:35:11Z

Disposition

← Older revision		Revision as of 18:35, 6 March 2020
Line 225:		Line 225:

	==Disposition==		==Disposition==
			*Most of these patients should be admitted and coordination should occur with hematology/oncology

	==See Also==		==See Also==

2020-03-06T18:34:07Z

Blinatumomab

2020-03-06T18:33:26Z

← Older revision		Revision as of 18:33, 6 March 2020
Line 131:		Line 131:

	===Panobinostat lactate (Farydak)===		===Panobinostat lactate (Farydak)===
	A*~~dverse~~ Events:		*Adverse Events:
	**[[Cytopenia]]		**[[Cytopenia]]
	**[[Diarrhea]]		**[[Diarrhea]]
Line 207:		Line 207:

	===Brentuximab vedotin (Adcetris)===		===Brentuximab vedotin (Adcetris)===
	*[[Progressive multifocal leukoencephalopathy]]		*Adverse Events:
	*[[Peripheral neuropathy]]		**[[Progressive multifocal leukoencephalopathy]]
	*[[Bone marrow suppression]]		**[[Peripheral neuropathy]]
			**[[Bone marrow suppression]]

	==Immunotoxin==		==Immunotoxin==
	===Moxetumomab pasudotox-tdfk (Lumoxiti)===		===Moxetumomab pasudotox-tdfk (Lumoxiti)===
	*[[Hemolytic uremic syndrome]]		*Adverse Events:
	*[[Capillary leak syndrome]]		**[[Hemolytic uremic syndrome]]
			**[[Capillary leak syndrome]]

	==Bispecific T-cell engager (Blincyto)==		==Bispecific T-cell engager (Blincyto)==
	===Blinatumomab===		===Blinatumomab===
	*[[CNS depression]]		*Adverse Events:
	*[[Cytokine release syndrome]]		**[[CNS depression]]
			**[[Cytokine release syndrome]]

	==Disposition==		==Disposition==

2020-03-06T18:31:37Z

2020-03-06T18:31:05Z

2020-03-06T18:24:59Z

Pembrolizumab (Keytruda)

2020-03-06T18:24:25Z

Pembrolizumab (Keytruda)

2020-03-06T18:24:05Z

CAR-T cells medications

← Older revision		Revision as of 18:24, 6 March 2020
Line 20:		Line 20:
	==CAR-T cells medications==		==CAR-T cells medications==
	===Tisagenlecleucel (Kymriah)===		===Tisagenlecleucel (Kymriah)===
	*Indications:		Indications:
	**Acute lymphoblastic leukemia		*Acute lymphoblastic leukemia
	**Large B-cell lymphoma		*Large B-cell lymphoma
			Adverse events include:
			*[[Cytokine release syndrome]]
			*[[Hypogammaglobulinemia]]
			*[[Pancytopenia]]
			*[[Altered mental status]]
			===Axicabtagene ciloleucel (Yescarta)===
			Indications:
			*Acute lymphoblastic leukemia
			*Large B-cell lymphoma
	*Adverse events include:		*Adverse events include:
	**[[Cytokine release syndrome]]		*[[Cytokine release syndrome]]
	**[[Hypogammaglobulinemia]]		*[[Pancytopenia]]
	**[[Pancytopenia]]		*[[Altered mental status]]
	**[[Altered mental status]]
	~~===Axicabtagene ciloleucel (Yescarta)===~~
	*Indications:
	**Acute lymphoblastic leukemia
	**Large B-cell lymphoma
	**Adverse events include:
	**[[Cytokine release syndrome]]
	**[[Pancytopenia]]
	**[[Altered mental status]]

	==PD1 Monoclonal Antibodies==		==PD1 Monoclonal Antibodies==

2020-03-06T18:23:31Z

Management